{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T10:31:00Z","timestamp":1761561060845},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2006,6,5]],"date-time":"2006-06-05T00:00:00Z","timestamp":1149465600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Fam Pract"],"published-print":{"date-parts":[[2006,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Ciclesonide is a new inhaled corticosteroids licensed for the prophylactic treatment of persistent asthma in adults. Currently beclomethasone dipropionate, budesonide and fluticasone propionate are the most commonly prescribed inhaled corticosteroids for the treatment of asthma but there has been no systematic review comparing the effectiveness and safety ciclesonide to these agents. We therefore aimed to systematically review published randomised controlled trials of the effectiveness and safety of ciclesonide compared to alternative inhaled corticosteroids in people with asthma.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>We performed literature searches on MEDLINE, EMBASE, PUBMED, the COCHRANE LIBRARY and various Internet evidence sources for randomised controlled trials or systematic reviews comparing ciclesonide to beclomethasone or budesonide or fluticasone in adult humans with persistent asthma. Data was extracted by one reviewer.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Five studies met the inclusion criteria. Methodological quality was variable. There were no trials comparing ciclesonide to beclomethasone. There was no significant difference between ciclesonide and budesonide or fluticasone on the following outcomes: lung function, symptoms, quality of life, airway responsiveness to a provoking agent or inflammatory markers. However, the trials were very small in size, increasing the possibility of a type II error. One trial demonstrated that the combined deposition of ciclesonide (and its active metabolite) in the oropharynx was 47% of that of budesonide while another trial demonstrated that the combined deposition of ciclesonide (and its active metabolite) in the oropharynx was 53% of that of fluticasone. One trial demonstrated less suppression of cortisol in overnight urine collection after ciclesonide compared to fluticasone (geometric mean fold difference = 1.5, P &lt; 0.05) but no significant difference in plasma cortisol response.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>There is very little evidence comparing CIC to other ICS, restricted to very small, phase II studies of low power. These demonstrate CIC has similar effectiveness and efficacy to FP and BUD (though equivalence is not certain) and findings regarding oral deposition and HPA suppression are inconclusive. There is no direct comparative evidence that CIC causes fewer side effects since none of the studies reported patient-based outcomes.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/1471-2296-7-34","type":"journal-article","created":{"date-parts":[[2006,6,6]],"date-time":"2006-06-06T07:22:30Z","timestamp":1149578550000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Inhaled ciclesonide versus inhaled budesonide or inhaled beclomethasone or inhaled fluticasone for chronic asthma in adults: a systematic review"],"prefix":"10.1186","volume":"7","author":[{"given":"Matthew J","family":"Dyer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David MG","family":"Halpin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ken","family":"Stein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2006,6,5]]},"reference":[{"key":"165_CR1","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1164\/ajrccm\/148.4_Pt_2.S1","volume":"148","author":"PJ Barnes","year":"1993","unstructured":"Barnes PJ, Pedersen S: Efficacy and safety of inhaled corticosteroids in asthma. Report of a workshop held in Eze, France, October 1992. Am Rev Respir Dis. 1993, 148: S1-26.","journal-title":"Am Rev Respir Dis"},{"key":"165_CR2","doi-asserted-by":"crossref","unstructured":"British guideline on the management of asthma. Thorax. 2003, 58 Suppl 1: i1-94. 10.1136\/thorax.58.suppl_1.1i.","DOI":"10.1136\/thx.58.suppl_1.i1"},{"key":"165_CR3","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1093\/fampra\/18.2.223","volume":"18","author":"M Eccles","year":"2001","unstructured":"Eccles M, Rousseau N, Higgins B, Thomas L: Evidence-based guideline on the primary care management of asthma. Fam Pract. 2001, 18: 223-229. 10.1093\/fampra\/18.2.223.","journal-title":"Fam Pract"},{"key":"165_CR4","unstructured":"National Asthma Education and Prevention Program. Expert Panel Report: Guidelines for the Diagnosis and Management of Asthma Update on Selected Topics--2002. J Allergy Clin Immunol. 2002, 110: S141-S219."},{"key":"165_CR5","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1016\/S0140-6736(02)11312-2","volume":"360","author":"AE Tattersfield","year":"2002","unstructured":"Tattersfield AE, Knox AJ, Britton JR, Hall IP: Asthma. Lancet. 2002, 360: 1313-1322. 10.1016\/S0140-6736(02)11312-2.","journal-title":"Lancet"},{"key":"165_CR6","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/S0091-6749(03)01859-1","volume":"112","author":"DB Allen","year":"2003","unstructured":"Allen DB, Bielory L, Derendorf H, Dluhy R, Colice GL, Szefler SJ: Inhaled corticosteroids: past lessons and future issues. J Allergy Clin Immunol. 2003, 112: S1-40. 10.1016\/S0091-6749(03)01859-1.","journal-title":"J Allergy Clin Immunol"},{"key":"165_CR7","doi-asserted-by":"publisher","first-page":"2160","DOI":"10.1210\/jcem.87.5.8447","volume":"87","author":"A Weinbrenner","year":"2002","unstructured":"Weinbrenner A, Huneke D, Zschiesche M, Engel G, Timmer W, Steinijans VW, Bethke T, Wurst W, Drollmann A, Kaatz HJ, Siegmund W: Circadian rhythm of serum cortisol after repeated inhalation of the new topical steroid ciclesonide. J Clin Endocrinol Metab. 2002, 87: 2160-2163. 10.1210\/jc.87.5.2160.","journal-title":"J Clin Endocrinol Metab"},{"key":"165_CR8","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1177\/0091270003260334","volume":"44","author":"S Rohatagi","year":"2004","unstructured":"Rohatagi S, Appajosyula S, Derendorf H, Szefler S, Nave R, Zech K, Banerji D: Risk-benefit value of inhaled glucocorticoids: a pharmacokinetic\/pharmacodynamic perspective. J Clin Pharmacol. 2004, 44: 37-47. 10.1177\/0091270003260334.","journal-title":"J Clin Pharmacol"},{"key":"165_CR9","first-page":"26","volume":"6","author":"LD Jackson","year":"1999","unstructured":"Jackson LD, Polygenis D, McIvor RA, Worthington I: Comparative efficacy and safety of inhaled corticosteroids in asthma. Can J Clin Pharmacol. 1999, 6: 26-37.","journal-title":"Can J Clin Pharmacol"},{"key":"165_CR10","first-page":"CD002310","volume-title":"Cochrane Database Syst Rev","author":"N Adams","year":"2004","unstructured":"Adams N, Bestall JM, Lasserson TJ, Jones PW: Inhaled fluticasone versus inhaled beclomethasone or inhaled budesonide for chronic asthma. Cochrane Database Syst Rev. 2004, CD002310-"},{"key":"165_CR11","volume-title":"Electronic Medicines Compendium","author":"EM Compendium","year":"2005","unstructured":"Compendium EM: Alvesco Product Information. Electronic Medicines Compendium. 2005, [http:\/\/emc.medicines.org.uk\/emc\/assets\/c\/html\/displaydoc.asp?documentid=15768]"},{"key":"165_CR12","first-page":"66","volume":"13","author":"MG Belvisi","year":"2004","unstructured":"Belvisi MG: Preclinical pharmacology of ciclesonide. European Respiratory Review. 2004, 13: 66-68.","journal-title":"European Respiratory Review"},{"key":"165_CR13","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1177\/0091270002250998","volume":"43","author":"S Rohatagi","year":"2003","unstructured":"Rohatagi S, Arya V, Zech K, Nave R, Hochhaus G, Jensen BK, Barrett JS: Population pharmacokinetics and pharmacodynamics of ciclesonide. J Clin Pharmacol. 2003, 43: 365-378. 10.1177\/0091270002250998.","journal-title":"J Clin Pharmacol"},{"key":"165_CR14","doi-asserted-by":"publisher","first-page":"479","DOI":"10.2165\/00003088-200443070-00004","volume":"43","author":"R Nave","year":"2004","unstructured":"Nave R, Bethke TD, van Marle SP, Zech K: Pharmacokinetics of [14C]ciclesonide after oral and intravenous administration to healthy subjects. Clin Pharmacokinet. 2004, 43: 479-486. 10.2165\/00003088-200443070-00004.","journal-title":"Clin Pharmacokinet"},{"key":"165_CR15","volume-title":"Eur J Clin Pharmacol","author":"R Nave","year":"2005","unstructured":"Nave R, Zech K, Bethke TD: Lower oropharyngeal deposition of inhaled ciclesonide via hydrofluoroalkane metered-dose inhaler compared with budesonide via chlorofluorocarbon metered-dose inhaler in healthy subjects. Eur J Clin Pharmacol. 2005"},{"key":"165_CR16","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1177\/0091270004271094","volume":"45","author":"K Richter","year":"2005","unstructured":"Richter K, Kanniess F, Biberger C, Nave R, Magnussen H: Comparison of the oropharyngeal deposition of inhaled ciclesonide and fluticasone propionate in patients with asthma. J Clin Pharmacol. 2005, 45: 146-152. 10.1177\/0091270004271094.","journal-title":"J Clin Pharmacol"},{"key":"165_CR17","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1378\/chest.127.3.851","volume":"127","author":"DK Lee","year":"2005","unstructured":"Lee DK, Fardon TC, Bates CE, Haggart K, McFarlane LC, Lipworth BJ: Airway and systemic effects of hydrofluoroalkane formulations of high-dose ciclesonide and fluticasone in moderate persistent asthma. Chest. 2005, 127: 851-860. 10.1378\/chest.127.3.851.","journal-title":"Chest"},{"key":"165_CR18","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1111\/j.1365-2125.2004.02108.x","volume":"58","author":"DK Lee","year":"2004","unstructured":"Lee DK, Haggart K, Currie GP, Bates CE, Lipworth BJ: Effects of hydrofluoroalkane formulations of ciclesonide 400 microg once daily vs fluticasone 250 microg twice daily on methacholine hyper-responsiveness in mild-to-moderate persistent asthma. Br J Clin Pharmacol. 2004, 58: 26-33. 10.1111\/j.1365-2125.2004.02108.x.","journal-title":"Br J Clin Pharmacol"},{"key":"165_CR19","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1006\/pupt.2001.0288","volume":"14","author":"F Kanniess","year":"2001","unstructured":"Kanniess F, Richter K, Bohme S, Jorres RA, Magnussen H: Effect of inhaled ciclesonide on airway responsiveness to inhaled AMP, the composition of induced sputum and exhaled nitric oxide in patients with mild asthma. Pulm Pharmacol Ther. 2001, 14: 141-147. 10.1006\/pupt.2001.0288.","journal-title":"Pulm Pharmacol Ther"},{"key":"165_CR20","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1034\/j.1399-3003.1999.14a08.x","volume":"14","author":"EF Juniper","year":"1999","unstructured":"Juniper EF, Guyatt GH, Cox FM, Ferrie PJ, King DR: Development and validation of the Mini Asthma Quality of Life Questionnaire. Eur Respir J. 1999, 14: 32-38. 10.1034\/j.1399-3003.1999.14a08.x.","journal-title":"Eur Respir J"},{"key":"165_CR21","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1056\/NEJM199201233260403","volume":"326","author":"R Schlaghecke","year":"1992","unstructured":"Schlaghecke R, Kornely E, Santen RT, Ridderskamp P: The effect of long-term glucocorticoid therapy on pituitary-adrenal responses to exogenous corticotropin-releasing hormone. N Engl J Med. 1992, 326: 226-230.","journal-title":"N Engl J Med"},{"key":"165_CR22","doi-asserted-by":"publisher","first-page":"477","DOI":"10.3109\/02770909909054553","volume":"36","author":"OD Wolthers","year":"1999","unstructured":"Wolthers OD, Honour JW: Measures of hypothalamic-pituitary-adrenal function in patients with asthma treated with inhaled glucocorticoids: clinical and research implications. J Asthma. 1999, 36: 477-486.","journal-title":"J Asthma"},{"key":"165_CR23","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/S0002-9343(99)80404-5","volume":"98","author":"NA Hanania","year":"1995","unstructured":"Hanania NA, Chapman KR, Kesten S: Adverse effects of inhaled corticosteroids. Am J Med. 1995, 98: 196-208. 10.1016\/S0002-9343(99)80404-5.","journal-title":"Am J Med"},{"key":"165_CR24","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1016\/S0091-6749(95)70254-7","volume":"96","author":"NA Hanania","year":"1995","unstructured":"Hanania NA, Chapman KR, Sturtridge WC, Szalai JP, Kesten S: Dose-related decrease in bone density among asthmatic patients treated with inhaled corticosteroids. J Allergy Clin Immunol. 1995, 96: 571-579. 10.1016\/S0091-6749(95)70254-7.","journal-title":"J Allergy Clin Immunol"},{"key":"165_CR25","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S0954-6111(05)80254-9","volume":"87 Suppl A","author":"NC Barnes","year":"1993","unstructured":"Barnes NC: Safety of high-dose inhaled corticosteroids. Respir Med. 1993, 87 Suppl A: 27-31.","journal-title":"Respir Med"},{"key":"165_CR26","volume-title":"Oxford Textbook of Medicine","author":"DAE Warrell","year":"2003","unstructured":"Warrell DAE: Oxford Textbook of Medicine. Edited by: Cox TM, Firth JD and Benz EJ. 2003, 2:"},{"key":"165_CR27","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1378\/chest.122.2.510","volume":"122","author":"CL Leach","year":"2002","unstructured":"Leach CL, Davidson PJ, Hasselquist BE, Boudreau RJ: Lung deposition of hydrofluoroalkane-134a beclomethasone is greater than that of chlorofluorocarbon fluticasone and chlorofluorocarbon beclomethasone : a cross-over study in healthy volunteers. Chest. 2002, 122: 510-516. 10.1378\/chest.122.2.510.","journal-title":"Chest"},{"key":"165_CR28","doi-asserted-by":"publisher","first-page":"iii, xi","DOI":"10.3310\/hta9290","volume":"9","author":"R Garside","year":"2005","unstructured":"Garside R, Stein K, Castelnuovo E, Pitt M, Ashcroft D, Dimmock P, Payne L: The effectiveness and cost-effectiveness of pimecrolimus and tacrolimus for atopic eczema: a systematic review and economic evaluation. Health Technol Assess. 2005, 9: iii, xi-iii,230.","journal-title":"Health Technol Assess"},{"key":"165_CR29","first-page":"C105","volume-title":"American Thoracic Society 99th International Conference","author":"LP Boulet","year":"2003","unstructured":"Boulet LP, Engelstatter R, Magyar P, Timar M, Knight A, Fabbri L: Ciclesonide is at least as effective as budesonide in the treatment of patients with bronchial asthma [abstract]. American Thoracic Society 99th International Conference. 2003, C105-"},{"key":"165_CR30","volume-title":"European Respiratory Journal","author":"D Ukena","year":"2003","unstructured":"Ukena D, Biberger C, Von BV, Malek R, Weber HH, Beck E, Linnhoff A: Ciclesonide significantly improves pulmonary function when compared with budesonide: a randomised 12 week study [Abstract]. European Respiratory Journal. 2003, 22:"},{"key":"165_CR31","first-page":"C105","volume-title":"American Thoracic Society 99th International Conference","author":"R Engelstatter","year":"2003","unstructured":"Engelstatter R, Benezet O, Kafe H, Ponitz HH, Hansel T, Cheung D, Steinijans VW, Barnes PJ: Comparative study in asthma patients treated with inhaled ciclesonide (80&micro;g or 320&micro;g once daily) or budesonide (200&micro;g twice daily) for 12 weeks [abstract]. American Thoracic Society 99th International Conference. 2003, C105-"},{"key":"165_CR32","first-page":"C105","volume-title":"American Thoracic Society 99th International Conference","author":"C Biberger","year":"2003","unstructured":"Biberger C, Von BV, Malek R, Weber HH, Beck E, Linnhoff A, Ukena D: Efficacy and safety of ciclesonide compared with budesonide in asthma patients: a randomized 12-week study [abstract]. American Thoracic Society 99th International Conference. 2003, C105-"},{"key":"165_CR33","volume-title":"European Respiratory Journal","author":"T Hansel","year":"2003","unstructured":"Hansel T, Engelstatter R, Benezet O, Kafe H, Ponitz HH, Cheung D, Barnes PJ: Once daily ciclesonide (80ug or 320ug) is equally effective as budesonide 200ug given twice daily: a 12 week study in asthma patients [Abstract]. European Respiratory Journal. 2003, 22:"},{"key":"165_CR34","doi-asserted-by":"publisher","first-page":"S119","DOI":"10.1016\/j.jaci.2003.12.418","volume":"113","author":"TC Fardon","year":"2004","unstructured":"Fardon TC, Lee DK, Gray RD, Currie GP, Haggart K, Bates CE, Lipworth BJ: Effects of hydrofluoralkane formulations of ciclesonide 320&micro;g once daily versus fluticasone propionate 220&micro;g twice daily on methacholine hyperresponsiveness in mild-to-moderate persistent asthma [Abstract]. Journal of Allergy and Clinical Immunology. 2004, 113: S119-10.1016\/j.jaci.2003.12.418.","journal-title":"Journal of Allergy and Clinical Immunology"},{"key":"165_CR35","doi-asserted-by":"publisher","first-page":"A768","DOI":"10.1164\/rccm.2204029","volume":"165","author":"R Pauwels","year":"2002","unstructured":"Pauwels R, Derom E, Van DVV, Marissens S, Vincken W: Effects of inhaled ciclesonide and fluticasone propionate on cortisol secretion and PC20 for adenosine in asthma patients [abstract]. American Journal of Respiratory and Critical Care Medicine. 2002, 165: A768-10.1164\/rccm.2204029.","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"key":"165_CR36","first-page":"147s","volume":"18","author":"E Derom","year":"2001","unstructured":"Derom E, Van DVV, Marissens S, Vincken W, Pauwels RA: Efficacy and systemic effects of ciclesonide and fluticasone in asthma patients. European Respiratory Journal. 2001, 18: 147s-","journal-title":"European Respiratory Journal"}],"container-title":["BMC Family Practice"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2296-7-34.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1471-2296-7-34\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2296-7-34","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2296-7-34.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:39:20Z","timestamp":1630456760000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcfampract.biomedcentral.com\/articles\/10.1186\/1471-2296-7-34"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,6,5]]},"references-count":36,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2006,12]]}},"alternative-id":["165"],"URL":"https:\/\/doi.org\/10.1186\/1471-2296-7-34","relation":{},"ISSN":["1471-2296"],"issn-type":[{"value":"1471-2296","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,6,5]]},"assertion":[{"value":"25 November 2005","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 June 2006","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 June 2006","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"34"}}